Steroid inhalers increase the risk of hard-to-treat infections
Older people who use steroid inhalers are more likely to suffer particular bacterial infections...
List view / Grid view
Older people who use steroid inhalers are more likely to suffer particular bacterial infections...
Engineers have devised a non-invasive way to assess a cell's mechanical properties simply by observation...
The National Institute for Health and Care Excellence (NICE) in England has recommended Teva Pharmaceutical Industries Ltd’s Cinqaero (reslizumab) in its Final Appraisal Determination (FAD).
The Asia-Pacific (APAC) asthma therapeutics market is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...
A defining characteristic of inhaled drug delivery is variability in the dose received by the patient, as a result of physiology, for example, or the technique applied during use. This variability directly affects clinical outcomes so reducing it to a minimum is an important goal for the industry...
22 December 2016 | By Niamh Louise Marriott, Digital Editor
Based on the results Orion is planning to apply for a marketing authorisation for the product in Europe. Orion currently estimates that the marketing...
3 October 2016 | By Peter Brady, CEO Orbital Media and Dr Martin Goldman, independent medical officer, Iatros Consulting
Dr Martin Goldman joins Peter Brady, Orbital Media's CEO, to discuss how to untap the potential of social media sourced real world evidence...
11 July 2016 | By Victoria White, Digital Content Producer
The FDA has approved Genentech’s Xolair (omalizumab) to treat moderate to severe persistent asthma in children six to 11 years of age...
18 May 2016 | By Katie Sadler
New data has revealed tiotropium improves lung function in children who continue to experience asthma symptoms despite taking other maintenance therapies.
17 March 2016 | By Victoria White
The VESTRI study compared Advair Diskus to fluticasone propionate monotherapy in children aged 4 – 11 years who have asthma...
15 March 2016 | By Victoria White
The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients...
The post-hoc analysis confirms the predictive nature of the relationship between baseline blood eosinophil counts and efficacy outcomes in patients treated with mepolizumab...
8 March 2016 | By Victoria White
The addition of Spiriva Respimat to other asthma maintenance therapies helps improve asthma symptom control regardless of allergy subtype...
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
29 February 2016 | By Victoria White
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled Phase III studies designed to evaluate the efficacy and safety of lebrikizumab...